

# 1 PD-1<sup>high</sup>CXCR5<sup>-</sup>CD4<sup>+</sup> Peripheral Helper T (Tph) cells Promote 2 Tissue-Homing Plasmablasts in COVID-19 3

4 Hiromitsu Asashima<sup>1, 2</sup>, Subhasis Mohanty<sup>3</sup>, Michela Comi<sup>1, 2</sup>, William E. Ruff<sup>1, 2</sup>, Kenneth B.  
5 Hoehn<sup>4</sup>, Patrick Wong<sup>2</sup>, Inessa Cohen<sup>1, 2</sup>, Sarah Coffey<sup>1, 2</sup>, Khadir Raddassi<sup>1, 2</sup>, Omkar  
6 Chaudhary<sup>3</sup>, Avraham Unterman<sup>5</sup>, Brinda Emu<sup>3</sup>, Steven H. Kleinstein<sup>2, 4, 6</sup>, Ruth R. Montgomery<sup>7</sup>,  
7 Akiko Iwasaki<sup>2, 3, 8</sup>, Charles S. Dela Cruz<sup>5</sup>, Naftali Kaminski<sup>5</sup>, Albert C. Shaw<sup>3</sup>, David A. Hafler<sup>1, 2,</sup>  
8 #, Tomokazu S. Sumida<sup>1, 2, #</sup>

## 9 10 Affiliations

- 11 1. Department of Neurology, Yale School of Medicine, New Haven, CT, USA
- 12 2. Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA
- 13 3. Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine,  
14 Yale University, New Haven, CT, USA.
- 15 4. Department of Pathology, Yale School of Medicine, New Haven, CT, USA.
- 16 5. Section of Pulmonary, Critical Care and Sleep Medicine Section, Department of Internal  
17 Medicine, School of Medicine, Yale University, New Haven, CT, USA.
- 18 6. Inter-Departmental Program in Computational Biology and Bioinformatics, Yale University,  
19 New Haven, CT, USA
- 20 7. Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
- 21 8. Howard Hughes Medical Institute, Chevy Chase, MD, USA.

## 22 23 #Corresponding author:

24 Dr. Tomokazu Sumida ([tomokazu.sumida@yale.edu](mailto:tomokazu.sumida@yale.edu)) or Dr. David Hafler  
25 ([david.hafler@yale.edu](mailto:david.hafler@yale.edu)) Departments of Neurology and Immunobiology, Yale School of  
26 Medicine, New Haven, CT, USA  
27 Phone: 203-747-4802  
28

29 **Summary**

30 A dysregulated immune response against coronavirus-2 (SARS-CoV-2) plays a critical role in  
31 the outcome of patients with coronavirus disease 2019 (COVID-19). A significant increase in  
32 circulating plasmablasts is characteristic of COVID-19 though the underlying mechanisms and  
33 its prognostic implications are not known. Here, we demonstrate that in the acute phase of  
34 COVID-19, activated PD-1<sup>high</sup>CXCR5<sup>-</sup>CD4<sup>+</sup> T cells, peripheral helper T cells, (Tph) are  
35 significantly increased and promote inflammatory tissue-homing plasmablasts in patients with  
36 stable but not severe COVID-19. Analysis of scRNA-seq data revealed that plasmablasts in  
37 stable patients express higher levels of tissue-homing receptors including CXCR3. The  
38 increased Tph cells exhibited “B cell help” signatures similar to that of circulating T follicular  
39 helper (cTfh) cells and promoted B cell differentiation *in vitro*. Compared with cTfh cells, Tph  
40 cells produced more IFN $\gamma$ , inducing tissue-homing chemokine receptors on plasmablasts.  
41 Finally, expansion of activated Tph cells was correlated with the frequency of CXCR3<sup>+</sup>  
42 plasmablasts in the acute phase of patients with stable disease. Our results demonstrate a  
43 novel role for Tph cells in acute viral immunity by inducing ectopic, antibody secreting  
44 plasmablasts.

45

46

47 **Key words:** PD-1<sup>high</sup>CXCR5<sup>-</sup>CD4<sup>+</sup> peripheral helper T (Tph) cells, tissue-homing  
48 plasmablasts, IFN $\gamma$ , COVID-19

## 49 Introduction

50 SARS-CoV-2 causes a wide spectrum of symptoms ranging from asymptomatic infections  
51 to acute respiratory distress syndrome (ARDS)<sup>1,2</sup>. COVID-19 is the clinical manifestation of  
52 SARS-CoV-2 infection and it has become clear that a dysregulated immune response against  
53 SARS-CoV-2 is central in determining disease severity. Increased frequencies of circulating  
54 neutrophils with low frequencies of natural killer cells or CD4<sup>+</sup> T cells are characteristic of  
55 peripheral blood immune profiles observed in patients with COVID-19<sup>3-6</sup>. The generation of a  
56 robust antibody response is critical for clearing the virus and alterations in B cell lineages with  
57 the expansion of plasmablasts are reported both in the blood and bronchoalveolar lavage of  
58 patients with COVID-19<sup>6-8</sup>. The increase in plasmablasts, which can represent up to 30% of  
59 circulating B cells, is observed in a subset of patients comparable to acute Ebola or dengue  
60 virus infections<sup>9,10</sup>.

61 During the acute phase of COVID-19, activated B cells differentiate into plasmablasts that  
62 migrate to target inflammatory tissues, especially the lungs<sup>11</sup>, indicating that trafficking patterns  
63 of plasmablasts are important in the disease course. These plasmablasts express tissue-  
64 specific chemokines together with adhesion molecules and produce organ-specific protective  
65 antibodies for viral control<sup>12,13</sup>. This rapid antibody response is critical as the early containment  
66 of virus reduces the risk of cytokine storm syndrome with excessive accumulation of immune  
67 cells in the lung parenchyma with ARDS. Despite this important role, the control of expansion  
68 and migration capacity of plasmablasts in patients with COVID-19 remains poorly understood.

69 During the adaptive immune response, T follicular helper (Tfh) cells play crucial roles  
70 in B cell differentiation<sup>14,15</sup>. Circulating CXCR5<sup>+</sup>CD4<sup>+</sup> T cells, termed cTfh cells, support B cell  
71 differentiation in blood while Tfh cells located in lymphoid tissues allow B cell differentiation in  
72 lymph nodes<sup>16</sup>. Intriguingly, while the plasmablast response correlates with the cTfh responses  
73 in subjects recovered from COVID-19<sup>17</sup>, there is no correlation between the frequency of cTfh  
74 cells and that of plasmablasts in symptomatic patients with COVID-19<sup>6</sup>. Moreover, in the acute  
75 phase of SARS-CoV-2 infection, a striking absence of germinal centers in lymphoid organs  
76 was reported, similar to SARS, but activation-induced cytidine deaminase (AID)-expressing B  
77 cells are still preserved<sup>18</sup>. These data suggest that activated helper T cells other than Tfh cells  
78 support the differentiation of B cells at extra-follicular regions in acute phase of COVID-19.

79 To examine the mechanism of T cell regulation of plasmablast differentiation in COVID-  
80 19, we investigated the characteristics of B and T cells in patients by single cell RNA-seq  
81 (scRNA-seq) and flow cytometry datasets. Here, we report that PD-1<sup>high</sup>CXCR5<sup>+</sup>CD4<sup>+</sup> T cells,

82 so called peripheral helper T (Tph) cells<sup>19,20</sup>, are significantly increased and positively  
83 correlated with the frequency of plasmablasts in peripheral blood in patients with COVID-19.  
84 These Tph cells exhibit “B cell help” signatures to a similar degree as cTfh cells, but also  
85 express more inflammatory chemokine receptors including *CCR2* and *CCR5*. *In vitro*  
86 experiments indicate that PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells have higher IFN $\gamma$  production, which  
87 promotes CXCR3 expression and differentiation of plasmablasts. Finally, we demonstrate that  
88 CXCR3<sup>+</sup> tissue-homing plasmablasts are significantly increased in patients with stable  
89 COVID-19 while they are decreased in patients with severe disease. These findings provide  
90 a mechanism for the increase of plasmablasts apart from Tfh cells in the acute phase of  
91 COVID-19. Thus, the induction of plasmablast trafficking to inflammatory sites by activated  
92 PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells is important for disease control in the acute phase of COVID-19.

93

## 94 **Results**

### 95 **Expanded plasmablasts express higher tissue-homing molecules in patients with** 96 **stable COVID-19**

97 We first confirmed that the frequency of plasmablasts is significantly increased in the  
98 peripheral blood in patients with COVID-19 by flow cytometry<sup>3,21</sup> (Figure 1a, Supplemental  
99 Table 1, 2). To further understand the characteristics of B cells in patients with COVID-19, we  
100 next analyzed previously collected scRNA-seq data<sup>5</sup> and sub-clustered B cells (total 13550  
101 cells from 31 samples) into eight clusters according to gene expression (Figure 1b, 1c,  
102 Supplemental Figure 1a, 1b, Supplemental Table 3). We identified naïve B cells  
103 (*MS4A1*<sup>+</sup>*IGHD*<sup>+</sup>), germinal center-like B cells (*MS4A1*<sup>+</sup>*NEIL1*<sup>+</sup>; GC-like B cells), intermediate  
104 memory B cells (*IGHD*<sup>+</sup>*CD27*<sup>+</sup>), memory B cells (*MS4A1*<sup>+</sup>*CD27*<sup>+</sup>), and two plasma cells  
105 clusters: plasmablasts (*MZB1*<sup>+</sup>*CD38*<sup>+</sup>) and Ki67<sup>+</sup> plasmablasts (*MZB1*<sup>+</sup>*CD38*<sup>+</sup>*MKI67*<sup>+</sup>), in  
106 accordance with a previous report<sup>22</sup> (plasmablasts; 912 cells and Ki67<sup>+</sup> plasmablasts; 537  
107 cells). GC-like B cells also express *CD9*<sup>23,24</sup> (Supplemental Figure 1b). Additionally, we were  
108 able to identify two additional clusters, namely, FCRL5<sup>+</sup> B cells (*MS4A1*<sup>+</sup>*FCRL5*<sup>+</sup>) and CD1c<sup>+</sup>  
109 B cells (*MS4A1*<sup>+</sup>*CD1C*<sup>+</sup>). FCRL5<sup>+</sup> B cells also express higher levels of *ITGAX* and *ZEB2* than  
110 the other B cells, and this cluster was similar with atypical B cells or double-negative (DN)  
111 cells<sup>25-27</sup> (Supplemental Figure 1b). CD1c<sup>+</sup> B cells express higher levels of *CD52* compared  
112 to the other B cell subclusters, which implies that gene expression signatures of this cluster  
113 resemble marginal zone-like B cells<sup>28,29</sup>. There was no significant difference in the clonal

114 diversity or the frequency of unmutated clones between the two clusters of plasmablasts  
115 (Supplemental Figure 1c, 1d). Both plasmablast clusters expressed IgG, which indicated that  
116 they had undergone class-switching (Figure 1d). Ki67<sup>+</sup> plasmablasts had a significantly lower  
117 frequency of somatic hypermutations (SHM) in COVID-19 subjects compared with the other  
118 plasmablasts (Figure 1e). The proportion of GC-like B cells was significantly decreased and  
119 FCRL5<sup>+</sup> B cells were increased in patients with progressive COVID-19. These observations  
120 imply that the extrafollicular response is related to B cell activation in patients with COVID-  
121 19<sup>30</sup> (Supplemental Figure 1e). To further examine the characteristics of each single cell RNA  
122 cluster, we determined gene expression levels as related to B cell function<sup>31</sup> (Supplemental  
123 Figure 1f). It was of interest that the expression level of *CXCR3*, the receptor necessary for  
124 trafficking to sites of inflammation, was upregulated in plasmablast clusters, especially in Ki67<sup>+</sup>  
125 plasmablasts. Homing receptors<sup>32</sup>, which promote homing to lymph nodes (*CCR7*, *SELL*),  
126 were highly expressed in healthy control plasmablasts, while Ki67<sup>+</sup> plasmablasts in stable  
127 COVID-19 patients expressed tissue-homing molecules (*CXCR3*, *CCR2*) (Figure 1f, 1g).  
128 Taken together, Ki67<sup>+</sup> plasmablasts trafficking to inflammatory sites are a unique population  
129 expanded in stable patients in contrast to patients with severe COVID-19, and these acute  
130 plasmablast responses might be beneficial for hosts to prevent viral expansion at inflammatory  
131 tissues.

132

### 133 **PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells are significantly increased in patients with COVID-19 and** 134 **have a unique gene expression profile**

135 Tfh cells provide essential B cell help during the adaptive immune response, and  
136 circulating Tfh (cTfh) cells share functional properties with Tfh cells<sup>16</sup>. Notably, PD-  
137 1<sup>high</sup>CXCR5<sup>-</sup> Tph cells, that are reported to be associated with extra follicular B cell  
138 differentiation<sup>20</sup>, were significantly increased in the blood of COVID-19 patients, in addition to  
139 significant increase in PD1<sup>high/int</sup>CXCR5<sup>+</sup> Tfh cells (Figure 2a, Supplemental Figure 2a, 2b).  
140 Tph cells were barely detected in healthy blood and moreover, correlated in COVID-19  
141 patients with the frequency of circulating plasmablasts (Figure 2b, Supplemental Figure 2c)  
142 but not with clinical characteristics (age, body mass index (BMI), and sex) (Supplemental  
143 Figure 3a-c). The increase of PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells and the positive correlation between  
144 these cells and plasmablasts in the acute phase of COVID-19 patients were validated from  
145 another dataset<sup>6</sup> (Supplemental Figure 4a-c).

146 To further characterize these T helper populations, six subsets of memory CD4<sup>+</sup> T cells  
147 (CD45RA<sup>-</sup> CD4<sup>+</sup> T cells), categorized by PD-1 and CXCR5 expression levels, were sorted and  
148 gene expression profiles were examined by bulk RNA-seq (Figure 2c). Principal component  
149 analysis (PCA) placed PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells at a distinctive position relative to other  
150 subsets, indicating a unique gene expression profile. PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells had similar  
151 expression of Tfh-related genes<sup>19</sup> compared to PD-1<sup>high</sup>CXCR5<sup>+</sup> Tfh cells and expressed  
152 molecules including *MAF*, *TIGIT*, *SLAMF6*, and *IL21*, which are important for Tfh functions  
153 (Figure 2d). PD-1<sup>int</sup>CXCR5<sup>+</sup> Tfh cells also expressed these genes, but had less *ICOS*  
154 expression than PD-1<sup>high</sup>CXCR5<sup>+</sup> Tfh cell, suggesting that PD-1<sup>high</sup>CXCR5<sup>+</sup> Tfh cells are more  
155 activated cTfh cells<sup>14</sup>. We identified 100 genes that were differentially expressed in PD-  
156 1<sup>high</sup>CXCR5<sup>-</sup> Tph cells compared with PD-1<sup>high</sup>CXCR5<sup>+</sup> Tfh cells ( $|\text{Log2FC}| > 1$ , FDR < 0.05)  
157 (Figure 2e); PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells showed marked upregulation of tissue-resident  
158 chemokine receptors, including *CCR2*, *CCR5* and *CX3CR1* (Figure 2f, Supplemental Figure  
159 3d). Additionally, we surveyed the expression of T cell lineage genes, and found that Th1-like  
160 signatures (*CXCR3*, *TBX21*, *STAT1*) were highly expressed in PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells  
161 (Supplemental Figure 3e). Thus, PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells exhibit “B cell help” signatures to  
162 a similar degree as cTfh cells, but with a unique gene expression profile.

163

#### 164 **PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells promote B cell differentiation, and produce more IFN<sub>γ</sub> than** 165 **PD-1<sup>high</sup>CXCR5<sup>+</sup> Tfh cells**

166 We examined whether PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells promote B cell differentiation *in*  
167 *vitro*. As with PD-1<sup>high</sup>CXCR5<sup>+</sup> Tfh cells, these cells induce memory B cells into plasmablasts,  
168 and initiated IgG production (Figure 3a, 3b). Stimulation with anti-CD3/CD28 antibodies  
169 induced greater IFN<sub>γ</sub> and IL-10 production from PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells (Figure 3c), which  
170 is of interest as IFN<sub>γ</sub> is known to upregulate *CXCR3* expression during B cell differentiation<sup>33</sup>.  
171 We observed that *CXCR3* expression on plasmablasts was upregulated in a dose dependent  
172 manner by IFN<sub>γ</sub> while IL-10 was not (Figure 3d, 3e). Moreover, besides *CXCR3*, other  
173 inflammatory tissue-homing receptors such as *CCR2* were upregulated, but *CXCR4* was not  
174 (Figure 3f). These data indicate that PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells promote B cell differentiation  
175 and have a capacity to induce plasmablasts which express homing-molecules for  
176 inflammatory tissues via IFN<sub>γ</sub> production.

177 **The proportion of activated PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells are significantly increased in**  
178 **stable as compared to severely ill patients with COVID-19 and are positively**  
179 **correlated with CXCR3<sup>+</sup> plasmablasts**

180 To investigate the characteristics of PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells *in vivo*, we evaluated the  
181 specific gene signatures of this subset (Supplemental Table 4). Compared to the other five  
182 subsets in memory CD4<sup>+</sup> T cells, *CXCR6*, *LAG3*, and *PRR5L* were significantly upregulated,  
183 while *CHD7*, *ZBTB20*, *ZNF251*, *GRK25*, and *GPRASP1* were significantly downregulated in  
184 PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells (Figure 4a, 4b). Flow cytometry analysis also showed the same  
185 trend of upregulation of LAG3 and CXCR6 expressions (Supplemental Figure 5a, 5b).  
186 Embedding these gene lists with CD4<sup>+</sup> T cell clusters from our scRNA-seq data set<sup>5</sup>, we found  
187 that dividing CD4<sup>+</sup> T cells best fit with these signatures (Figure 4c). We previously reported  
188 that dividing CD4<sup>+</sup> T cells share the characteristics of HLA-DR<sup>+</sup>CD38<sup>+</sup> activated T cells<sup>5</sup>, and  
189 indeed, more than half of the activated CD4<sup>+</sup> T cells were in the PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cell  
190 population (Figure 4d). In contrast, 15% of PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells exhibited an activated  
191 state among all COVID-19 samples (data not shown), with a significantly higher proportion in  
192 patients with stable disease as compared to patients with progressive disease (Figure 4e). We  
193 confirmed that these observations were not highly confounded by known risk factors for  
194 disease severity, such as age, BMI, and sex (Supplemental Figure 5c-e).

195 Finally, we observed a positive correlation between activated PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells  
196 and CXCR3<sup>+</sup> plasmablasts (Figure 4f). There was no difference in the proportion of PD-  
197 1<sup>high</sup>CXCR5<sup>-</sup> Tph cells between stable and progressive patients at baseline, but interestingly  
198 they increased in progressive patient over time and reached significance at two weeks after  
199 the baseline (Supplemental Figure 5f, Supplemental Table 5). In contrast, the significantly  
200 elevated frequency of activated PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells in stable patients at baseline  
201 became less significant over time (Supplemental Figure 5g). These data demonstrate that  
202 prompt increased HLA-DR<sup>+</sup>CD38<sup>+</sup> activated PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells are one of the early  
203 responses in stable patients, which is also positively correlated with tissue-homing CXCR3<sup>+</sup>  
204 plasmablasts.

205

## 206 Discussion

207 Here, we performed a bidirectional-analyses between T cells and B cells in patients with  
208 COVID-19 by both bulk and scRNA-seq studies with B-cell receptor (BCR) repertoire analysis  
209 and *in vitro* assays. PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells were increased among the PBMCs of patients  
210 with COVID-19 and were positively correlated with the frequency of plasmablasts. These PD-  
211 1<sup>high</sup>CXCR5<sup>-</sup> Tph cells had a similar gene profile with cTfh cells focused on “B cell help”  
212 signatures and promoted B cell differentiation *in vitro*. Moreover, CXCR3<sup>+</sup> tissue-homing  
213 plasmablasts were markedly increased in patients with stable but not severely ill patients with  
214 COVID-19 where we hypothesize that activated PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells promoted these  
215 plasmablasts via IFN $\gamma$  production. Thus, these data suggest that tissue homing plasmablasts  
216 are important for the clinical outcome of patients with COVID-19 (Supplemental Figure 6).

217 PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells were first described in the synovial fluid of rheumatoid arthritis  
218 and the peripheral blood of patients with systemic lupus erythematosus (SLE)<sup>19,34</sup>, indicating  
219 an important role in autoimmune diseases with tissue specific, ectopic antibody production.  
220 Our data extend those findings, demonstrating a role for these Tph cells in acute viral  
221 infections. We show that not only PD-1<sup>high/int</sup>CXCR5<sup>+</sup> cTfh cells, but also PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph  
222 cells are significantly increased in peripheral blood of COVID-19 patients supporting the  
223 expansion of plasmablasts. One of the common signals between the acute phase of COVID-  
224 19 and chronic autoimmune conditions such as SLE are type-1 interferon (IFN)  
225 signatures<sup>5,35,36</sup>. Type-1 IFN (IFN-I) is reported to downregulate CXCR5 expression on human  
226 T cells<sup>37</sup> and our recent data showed that IFN-I upregulates PD-1 expression and  
227 downregulates CXCR5 expression in an *in vitro* assay<sup>38</sup>. Intriguingly, most of the genes unique  
228 to PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells such as *CXCR6*, *LAG3*, *ZBTB20*, and *CHD7* had the same  
229 directions for their expression levels after type-1 IFN stimulation<sup>38</sup>. These data indicate that  
230 type-1 IFN might be one of the key signals to induce these Tph cells.

231 Patients with COVID-19 have a striking loss of GCs in lymph nodes with underlying  
232 extrafollicular B cell responses, particularly in severe cases<sup>18,39</sup>. Our scRNA-seq data showed  
233 an increase in FCRL5<sup>+</sup> B cells in progressive patients (Supplemental Figure 1e), which  
234 supports this observation. Our results highlight the characteristics of PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells  
235 as: 1) lacking CXCR5 expression, important for the entry in GCs; 2) producing more IFN $\gamma$  that  
236 is similar to T cells residing in the extra-follicular regions of lymph nodes<sup>18</sup>; and 3) exhibiting



237 highly overlapping signatures with dividing CD4<sup>+</sup> T cells that are positively correlated with the  
238 proportion of Ki67<sup>+</sup> plasmablasts<sup>40</sup>, which had lower SHM frequencies in our scRNA-seq data.  
239 These findings suggest that circulating PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells may be the counterpart of T  
240 cells which promote more extra-follicular responses<sup>20</sup>. On the other hand, we could detect  
241 these T cells in peripheral blood of stable COVID-19 patients despite the lack of extrafollicular  
242 signatures in such patients. In acute viral infections, extra-follicular responses are thought to  
243 bridge between innate- and GC-responses of B cells<sup>41</sup>. Many effector molecules control the  
244 switch between GC- and extra-follicular responses<sup>42</sup>, which is dynamically changed in the  
245 acute phase of COVID-19. Though it might be difficult to conclude the direct relationship  
246 between extra-follicular responses and blood PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells from our dataset, the  
247 longitudinal assessment of these T cells together with their spatial analysis with B cells in  
248 lymph nodes will clarify these relationships.

249 In the *Salmonella* infected mouse model, the antibody responses important for the  
250 bacteria clearance are established by day 3 through 5 weeks, and GC formation is observed  
251 approximately one month after infection, indicating GC formation is not necessary for these  
252 early responses<sup>43</sup>. Similarly, in COVID-19 human samples, earlier antibody responses are  
253 likely to be associated with better recovery<sup>44,45</sup>, which is consistent with our findings that the  
254 rapid induction of inflammatory tissue-homing plasmablasts was linked with a better clinical  
255 outcome. Additionally, we detected that PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells in the activated state had  
256 the capacity to support the induction of tissue-homing plasmablasts, and these T cells were  
257 significantly increased in stable patients at the earlier stage of disease. The significant  
258 difference in the frequency of activated PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells between stable and  
259 progressive patients disappears over time, indicating that the prompt induction of activated  
260 PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells might be critical for the promotion of tissue homing plasmablasts to  
261 effectively remove virus from inflamed tissues and thus linked with better clinical outcomes.  
262 Not only sex differences<sup>3</sup>, but also genetic backgrounds are reported to be related to T cell  
263 activation<sup>46,47</sup> and further analyses combined with these factors will lead to the more precise  
264 identification of patients at higher risk, and thus expected to be valuable for the development  
265 of personalized treatments.

266 Finally, our investigations have implications for understanding T-B cell interaction in  
267 human viral infections and provide a potential framework for assessing immune response to

268 SARS-CoV-2 and other IFN-I inducing viral infections. In summary, our data implicate PD-  
269  $1^{\text{high}}\text{CXCR5}^-$  Tph cells as triggering acute protective plasmablast responses with direct  
270 relevance in COVID-19 pathophysiology. Moreover, these data shed light on how T cells can  
271 affect B cell differentiation in COVID-19 and provide potential insights into the role of PD-  
272  $1^{\text{high}}\text{CXCR5}^-$  Tph cells on a variety of immune-mediated diseases with possible contribution of  
273 aberrant T-B interaction, including chronic autoimmune diseases.

274

275 **Methods**

276 **Ethics Statement**

277 This study was approved by the Institutional Review Board at the Yale School of Medicine  
278 (2000027291REG and FWA00002571, Protocol ID. 2000027690). Informed consent was  
279 obtained from all enrolled patients, healthcare workers and healthy donors.

280

281 **Patients and Samples**

282 Adult patients ( $\geq 18$  years old) admitted to Yale-New Haven Hospital, positive for SARS-CoV-  
283 2 by RT-PCR from nasopharyngeal and/or oropharyngeal swabs, and able to provide informed  
284 consent (surrogate consent accepted) were eligible (Supplemental Table 1). Individuals with  
285 active chemotherapy against cancers, pregnant patients, patients with background  
286 hematological abnormalities, patients with autoimmune diseases and patients with a history  
287 of organ transplantation and on immunosuppressive agents, were excluded from this study.  
288 For the characterization of T cells and B cells, the flow data deposited in the Yale IMPACT  
289 Biorepository study were analyzed as described elsewhere<sup>3,21</sup>. All the patients were admitted  
290 between 30 March and 27 May 2020 and hospitalized. Only the baseline data were analyzed  
291 except for the analysis of time kinetics (Supplemental Table 2). All the experiments were  
292 performed on fresh peripheral blood mononuclear cells (PBMCs), and samples were drawn  
293 on the average of 11.8 days after first symptoms. 92 patients with COVID-19 and 64 COVID-  
294 19-uninfected healthcare workers (HCs) were enrolled. COVID-19 patients who required  
295 admission to the ICU had been classified as “progressive” and 27.8% of them were expired.  
296 The other patients classified as “stable” were all discharged without ICU admission. For the  
297 patients who are 90 years-old or older, their ages were protected health information, and ‘90’  
298 was put as the surrogate value for the analyses. HCs were all negative in both PCR and  
299 serology tests.

300 Single cell RNA-seq (scRNA-seq) was performed on cryopreserved PBMC samples of  
301 10 patients with COVID-19 following the same criteria as above and 13 age- and sex- matched  
302 controls. All the samples were drawn on the average of 11.7 days after first symptoms. Control  
303 samples were already collected before the first report of COVID-19 in 2018. From eight of ten  
304 patients with COVID-19, PBMC samples from two different time points had been analyzed.  
305 Four patients had been classified as “progressive”, who required admission to the ICU, and

306 the other six patients classified as “stable” who were hospitalized and all discharged, and the  
307 same criteria as flow data. We have described the full cohort elsewhere<sup>5</sup>.

308 All the other experiments which include *in vitro* experiments and bulk RNA-seq were  
309 performed with fresh PBMCs at the baseline. All the patients were admitted between 21<sup>st</sup> July  
310 and 22<sup>nd</sup> Jan 2021.

311

### 312 **Peripheral blood mononuclear cells isolation**

313 PBMCs were prepared from whole blood by Ficoll gradient centrifugation (Histopaque (Sigma)  
314 in the Yale IMPACT Biorepository study and Lymphoprep (Stemcell) in other experiments).  
315 The PBMC layer was collected into a new 50-ml tube and washed twice with PBS to remove  
316 any remaining Lymphoprep/Histopaque. As for scRNA-seq and flow cytometry, the pelleted  
317 cells were treated with ACK buffer for red cell lysis. All the other experiments including bulk  
318 RNA-seq samples were processed without lysis buffer.

319

### 320 **Flow Cytometry and sorting**

321 In the Yale IMPACT Biorepository study, the staining was performed mainly in two separate  
322 panels for (1) T cell surface staining and (2) B cell surface staining. PBMCs were plated at 1-  
323  $2 \times 10^6$  cells in a 96-well U-bottom plate, and resuspended in Live/Dead Fixable Aqua  
324 (ThermoFisher) for 20 min at 4 °C. Following a wash, cells were then blocked with Human  
325 TruStan FcX (BioLegend) for 10 min at room temperature. Cocktails of desired staining  
326 antibodies were directly added to this mixture for 30 min at room temperature. Before analysis,  
327 cells were washed and resuspended in 100 µl of 4% paraformaldehyde for 30 min at 4 °C. We  
328 have described the detailed methods elsewhere<sup>3</sup>. The adopted antibodies and their clones  
329 were as follows. Anti-CD3 (UCHT1), anti-CD19 (SJ25C1), anti-CD4 (SK3), anti-CD45RA  
330 (HI100), anti-PD-1 (EH12.2H7), anti-CD38 (HIT2), anti-CXCR5 (RF8B2), anti-CXCR3  
331 (1C6/CXCR3), anti-CD20 (2H7), anti-CD27 (M-T271), anti-IgD (IA6-2).

332 For other experiments, freshly isolated PBMCs were stained with cocktails of desired  
333 staining antibodies for 30 minutes at 4°C. Specific T cell and B cell subsets were sorted on a  
334 Sony MA900 cell sorter. The adopted antibodies and their clones were as follows. Anti-CD4  
335 (OKT4), anti-CD19 (HIB19), anti-CD20 (2H7), anti-CD27 (M-T271), anti-CD38 (HIT2), anti-  
336 CD138 (MI15), anti-PD-1 (EH12.2H7), anti-LAG3 (11C3C65), anti-CCR2 (K036C2), ant-CCR5

337 (J418F1), anti-CXCR3 (G025H7), anti-CXCR6 (K041E5), anti-CX3CR1 (2A9-1) (all from  
338 Biologend); anti-CD3 (UCHT1), anti-CD45RA (HI100), anti-CXCR5 (RF8B2) (all from BD  
339 Biosciences).

340

#### 341 **T-B-cell co-culture experiments**

342 Co-culture experiments were performed referenced as described previously<sup>19</sup>. In brief, sorted  
343 T cell populations (5000-10000 cells) from PBMCs of patients with COVID-19 were co-cultured  
344 with autologous CD20+CD27+ memory B cells at a ratio of 1:3 in 200 µl of RPMI 1640 medium  
345 (Gibco) supplemented with 10% fetal bovine serum (FBS), 2 nM L-glutamine, and 100 U/ml  
346 penicillin, 100 µg/ml streptomycin (Lonza), stimulated with SEB (1 µg/ml) and LPS (1 µg/ml)  
347 for 7 days. Supernatants were collected, and total IgG (Invitrogen) was measured by ELISA.  
348 Cells were harvested and analyzed by flow cytometry, with plasma cells defined as  
349 CD27<sup>high</sup>CD138<sup>+</sup> cells.

350

#### 351 **B cell differentiation *in vitro***

352 We extracted PBMCs from healthy volunteers. After the isolation of CD19+ B cells from  
353 PBMCs using Human B cell isolation kit (Stemcell Technologies), CD20+CD27+ memory B  
354 cells were sorted on a FACS Aria (BD Biosciences) and stimulated with CD40L (0.05 µg/ml)  
355 (Enzo), IL-21 (20 ng/ml) (R&D systems) and other cytokines (all from R&D systems) in culture  
356 medium the same as above. After 7 days, CD27<sup>high</sup>CD138+ plasma cells were sorted for gene  
357 expression analysis by qPCR.

358

#### 359 **T cell stimulation *in vitro***

360 We extracted PBMCs from patients with COVID-19. Each subset of memory CD4+ T cells  
361 based on the expression levels of PD-1 and CXCR5 were stimulated with anti-CD3/CD28  
362 (each 1 µg/ml; BD Biosciences) for 48 hrs and cytokine levels were measured by ELISA (all  
363 from R&D systems) according to the manufacturer's instructions. 1% Triton X-100 for 60  
364 minutes at room temperature was added before ELISA to reduce risk from any potential virus  
365 in the supernatant<sup>48</sup>.

366

### 367 **Quantitative PCR**

368 Total RNA was extracted using RNeasy Micro Kit (QIAGEN) according to the manufacturer's  
369 instructions. cDNA was synthesized with SuperScript IV VILO Master Mix (Invitrogen). cDNAs  
370 were amplified with Taqman probes (Taqman Gene Expression Arrays) and TaqMan Fast  
371 Advanced Master Mix on a StepOne Real-Time PCR System (Applied Biosystems) according  
372 to the manufacturer's instructions. The RNA expression was measured relative to *B2M*  
373 expression. The adopted Taqman probes were as follows. *CXCR3* (Hs01847760\_s1), *CXCR4*  
374 (Hs00607978\_s1), *CCR2* (Hs00356601\_m1).

375

### 376 **Single cell RNA-seq data processing**

377 A PBMC scRNA-seq data set which had been previously performed and reported by us<sup>5</sup> was  
378 reanalyzed. In brief, single cell barcoding of PBMC and library construction had been  
379 performed using the 10x Chromium NextGEM 5 prime kit according to manufacturer's  
380 instructions. Libraries had been sequenced on an Illumina Novaseq 6000 platform. Raw reads  
381 had been demultiplexed and processed using Cell Ranger (v3.1) mapping to the GRCh38  
382 (Ensembl 93) reference genome. Resulting gene-cell matrices had been analyzed using the  
383 package Seurat<sup>49,50</sup> in the software R (v3.6.2) including integration of data, clustering, multiplet  
384 identification and cell type annotation. We have described the detailed methods elsewhere<sup>5</sup>.  
385 The annotated R object was used for sub-clustering of B cells.

386 The three cell populations, "Memory B cells", "Naïve B cells " and "Plasma cells" in  
387 total PBMCs were re-clustered to obtain a finer cell type granularity. To remove batch- and  
388 single-donor effects, we integrated all 31 samples of these populations into one dataset using  
389 reference-based anchor finding and integration workflow. We chose 2 healthy donor samples  
390 (C27 and C32) and 2 COVID-19 samples (NS1B and TS3A), which have enough B cell  
391 numbers, as references for anchor finding and integration. The top 2000 variable genes were  
392 selected, and integration anchors were determined by "FindIntegrationAnchors" without k.filter  
393 for low cell numbers in some samples. These anchors were used to integrate the data using  
394 the "IntegrateData" function with top 30 dimensions and scaled. The top 17 PCs were used  
395 for data integration and downstream steps, along with a clustering resolution of 0.4. Cluster-

396 specific gene expression profiles were established using the “FindAllMarkers” per cluster and  
397 per subset to annotate the clusters. Doublet clusters were determined by co-expression of  
398 heterogeneous lineage markers (e.g., *MS4A1* and *CD3*). These clusters were removed prior  
399 to finalizing the UMAPs.

400

#### 401 **B cell receptor repertoire analysis**

402 B cell receptor (BCR) V(D)J repertoire data processing, clonal clustering, and unmutated  
403 germline ancestor sequence reconstruction was previously performed in<sup>5</sup>. Briefly, V(D)J  
404 genes aligned to the IMGT/GENE-DB v3.1.26<sup>51</sup> germline reference database using IgBLAST  
405 v.1.15.0<sup>52</sup>. Cells with multiple IGH V(D)J sequences were assigned to the most abundant  
406 IGH V(D)J sequence by UMI count, and ties were broken by the first identified heavy chain.  
407 Non-functional sequences were removed. V(D)J sequences within each patient were  
408 grouped into clonal clusters by first partitioning based on common IGHV gene annotations,  
409 IGHJ gene annotations, and junction lengths. Within these groups, sequences differing from  
410 one another by a length normalized Hamming distance of 0.15 within the junction region  
411 were defined as clones by single-linkage clustering using Change-O v.1.0.0<sup>53</sup>. Germline  
412 sequences were reconstructed for each clone with the D segment and N/P regions masked  
413 (replaced with “N” nucleotides) using the CreateGermlines.py function within Change-O  
414 v.1.0.0.

415 Somatic hypermutation frequency was calculated using SHazaM v1.0.2.999<sup>54</sup> as the  
416 frequency of non-ambiguous nucleotide differences along the IGHV gene segment (IMGT  
417 positions 1-312) between each sequence and its inferred germline ancestor. To identify  
418 unmutated B cell clones of different cell types and isotypes, B cell clones were separated by  
419 cell type and isotype and considered “unmutated” if the median somatic hypermutation  
420 frequency of their constituent sequences was < 1%. This cutoff was also used in<sup>5,55</sup>. To  
421 quantify B cell clonal diversity, we calculated Simpson’s diversity within each patient for  
422 plasmablast subsets using the alphaDiversity function of Alakazam v1.0.2.999<sup>53</sup>. To account  
423 for differences in sequence depth, the number of sequences within each patient were down-  
424 sampled to the same number of sequences, and the mean of 100 such re-sampling  
425 repetitions was reported. Only patients with at least 30 B cells were included in diversity  
426 calculations. All statistical analyses of BCR sequences were performed with R (v3.6.1).

427

428

## 429 **Bulk RNA-seq**

### 430 *cDNA and library preparation and sequencing:*

431 RNAs were isolated using RNeasy Plus Micro Kit (QIAGEN) and cDNAs were generated  
432 using the SMART-Seq v4 Ultra Low Input RNA Kit for sequencing (Takara/Clontech).  
433 Barcoded libraries were generated by the Nextera XT DNA Library Preparation kit (Illumina)  
434 and sequenced with a 2x100 bp paired-end protocol on the HiSeq 4000 Sequencing System  
435 (Illumina).

436

### 437 *Bulk RNA-seq data analysis:*

438 Low quality ends (less than phred score=30) and short read length (minimum length=30)  
439 was trimmed using PRINSEQ++<sup>56</sup> (version1.2). Trimmed reads were aligned to the hg38  
440 genome reference using STAR<sup>57</sup> (v2.7.1), and subsequently RSEM (RNA-Seq by  
441 Expectation-Maximization)<sup>58</sup> was used to count reads mapping to the genes from Ensembl  
442 release 93. Top 1000 genes by variance were analyzed for PCA. Heat maps show row-  
443 normalized relative gene expression z-scores across columns. Pairwise differential  
444 expression was performed using the R package DESeq2<sup>59</sup>. The cutoff value to select  
445 differentially expressed genes is provided in each figure legend.

446 These data will be publicly available prior to publication .

447

## 448 **Statistical analysis**

449 All statistical analyses were performed using R or GraphPad Prism 7 (GraphPad Software).  
450 Detailed information about statistical analysis, including tests and values used, is provided  
451 in the figure legends.

452



## 453 **Figure Legends**

454

### 455 **Figure 1**

#### 456 **The divergent immunological features of B cells in stable and progressive COVID-19** 457 **patients.**

458 Plasmablasts of patients with stable COVID-19 express inflammatory tissue-homing  
459 receptors. **a**, Representative flow data of CD19<sup>+</sup>CD27<sup>+</sup>CD38<sup>+</sup> plasmablasts (left). The  
460 proportion of plasmablasts between healthcare workers (HCs) (n=15) and both stable and  
461 progressive COVID-19 patients (COVID) (n=51) were evaluated by two-tailed unpaired  
462 Student's t-test were evaluated (right). **b**, UMAP representation of sub-clustered B cells from  
463 HCs (n = 13) and COVID-19 samples (n = 18 from 10 patients). Eight subclusters were  
464 identified. **c**, Canonical cell markers for cluster delineation. Data are colored according to  
465 expression levels. **d**, Fractional abundance of IGHA (dark green), IGHD (orange), IGHG (pink),  
466 and IGHM (light green) cells in each cluster. PBs denote plasmablasts. **e**, Frequency of  
467 somatic hypermutation (SHM) in each cluster. Each dot denotes a patient (combined early and  
468 late samples, n=10). A Wilcoxon test was evaluated, and p value is reported above  
469 plasmablast clusters. PBs denote plasmablasts. **f**, Heatmap of tissue-homing receptors<sup>32</sup>  
470 among HC, stable COVID-19 (stable), and progressive COVID-19 (progressive) in clusters of  
471 both plasmablasts and Ki67<sup>+</sup> plasmablasts. Average expression per subject for each gene is  
472 shown. **g**, Representative flow data of CXCR3 expression on CD19<sup>+</sup>CD27<sup>+</sup>CD38<sup>+</sup>  
473 plasmablasts in COVID-19 patients (left). The proportions of CXCR3<sup>+</sup> plasmablasts between  
474 stable (n= 31) and progressive (n=20) COVID-19 patients were evaluated by two-tailed  
475 unpaired Student's t-test (right).

476

### 477 **Figure 2**

#### 478 **The characteristics of PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells**

479 PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells have characteristic gene expressions and are increased in COVID-  
480 19 patients. **a**, Representative flow data of PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells in each group (left), the  
481 proportion of these T cells among healthcare workers (HC) (n=55), stable COVID-19 patients  
482 (Stable) (n=56), and progressive patients (Progressive) (n=36). One-way ANOVA with Dunn's  
483 multiple comparisons tests were performed to evaluate differences (right). **b**, Correlation  
484 between PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells (percentage of CD3<sup>+</sup>CD4<sup>+</sup>CD45RA<sup>-</sup> memory T cells) and

485 plasmablasts (percentage of CD19<sup>+</sup> B cells) in COVID-19 patients (both stable and  
486 progressive, n=51). Linear regression is shown with 95% confidence interval (gray area).  
487 Correlation statistics is two-tailed Spearman's rank correlation test. **c**, Principal component  
488 analysis (PCA) of RNA-seq transcriptomes (n=3, COVID-19 patients). Based on the  
489 expression levels of PD-1 and CXCR5, six subsets (i)-(vi) were evaluated **d**, Heatmap of  
490 Tfh-related genes<sup>19</sup> among six subsets of memory CD4<sup>+</sup> T cells. **e**, Clustered heatmap of 100  
491 genes that were differentially expressed (left column) in PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells compared  
492 with cTfh cells (PD-1<sup>high</sup>CXCR5<sup>+</sup> Tph cells) ( $|\text{Log}_2\text{FC}| > 1$ , FDR < 0.05). The right column shows  
493 the log<sub>2</sub> fold change for PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells compared to cTfh cells. **f**, Representative  
494 flow data of CCR5 and CCR2 expression on PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells compared with PD-  
495 1<sup>high</sup>CXCR5<sup>+</sup> Tph cells.

496

### 497 **Figure 3**

#### 498 **The functions of PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells**

499 PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells promote B cell differentiation and produce IFN $\gamma$  much higher than  
500 cTfh cells, which affects the expression levels of tissue-homing receptors on plasmablasts. **a**-  
501 **b**, Each T cell subset and autologous CD20<sup>+</sup>CD27<sup>+</sup> B cells were sorted and co-cultured with  
502 SEB and LPS for 7 days (n=5, COVID-19 patients). Representative flow data of  
503 CD27<sup>high</sup>CD138<sup>+</sup> plasma cells after co-culture (**a**). IgG concentrations in supernatants of co-  
504 cultures were evaluated by One-way ANOVA with Dunn's multiple comparisons tests (**b**). **c**,  
505 Sorted T cells (n=4, COVID-19 patients) were stimulated with anti-CD3/28 (each 1  $\mu\text{g}/\text{ml}$ ) for  
506 48 hrs, then cytokine production levels were measured (IFN $\gamma$ , IL-17A, IL-10). **d-f**, Sorted  
507 CD20<sup>+</sup>CD27<sup>+</sup> memory B cells (n=5, healthy donors) were cultured with CD40L (0.05 ng/ml),  
508 IL-21 (20ng/ml), and IL-10 (10 ng/ml) or different concentration of IFN $\gamma$  (0, 3, 10, 30 ng/ml) for  
509 7 days (n=5, healthy controls). Representative histogram of flow data for CXCR3 expression  
510 on plasma cells (**d**, left), CXCR3 gMFI was evaluated by One-way ANOVA with Tukey's  
511 multiple comparisons tests (**d**, right). After 7 days in culture, CD19<sup>+</sup>CD27<sup>+</sup>CD138<sup>+</sup> plasma cells  
512 were sorted and gene expression measured relative to *B2M* by qPCR (**e**, **f**). The expression  
513 levels were evaluated by One-way ANOVA with Tukey's multiple comparisons tests (**c-f**).

514

515

516

517 **Figure 4**  
518 **Activated PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells are significantly increased in stable COVID-19**  
519 **patients and positively correlated with CXCR3<sup>+</sup> plasmablasts.**  
520 **a**, Venn diagrams showing the overlapped genes among those significantly upregulated  
521 (Log2FC>1, FDR<0.05) (left) and downregulated (Log2FC<-1, FDR<0.05) (right) in PD-  
522 1<sup>high</sup>CXCR5<sup>-</sup> Tph cells compared with five subsets as indicated. **b**, Heatmap of PD-  
523 1<sup>high</sup>CXCR5<sup>-</sup> Tph cells-related genes (selected in **a**) among each T cell subset from RNA-seq  
524 data. **c**, Heatmap of PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells-related genes (selected in **a**) among each T  
525 cell cluster of our scRNA-seq dataset reported<sup>5</sup>. **d**, Representative flow data for each T cell  
526 subset among HLA-DR<sup>+</sup>CD38<sup>+</sup>CD45RA<sup>-</sup>CD4<sup>+</sup> T cells (left), and their proportions were  
527 evaluated by One-way ANOVA with Dunn's multiple comparisons tests (right). COVID-19  
528 samples which have more than 5% of HLA-DR<sup>+</sup>CD38<sup>+</sup> T cells among memory CD4<sup>+</sup> T cells  
529 were evaluated (n=11). **e**, Representative flow data of HLA-DR<sup>+</sup>CD38<sup>+</sup> activated cells in PD-  
530 1<sup>high</sup>CXCR5<sup>-</sup> Tph cells between stable and progressive COVID-19 patients (up). The  
531 proportions of activated PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells were evaluated (stable; n= 56, progressive;  
532 n= 36) by two-tailed unpaired Student's t-test (down). **g**, Correlation between activated PD-  
533 1<sup>high</sup>CXCR5<sup>-</sup> Tph cells (percentage of CD3<sup>+</sup>CD4<sup>+</sup>CD45RA<sup>-</sup> memory T cells) and CXCR3<sup>+</sup>  
534 plasmablasts (percentage of CD19<sup>+</sup>CD27<sup>+</sup>CD38<sup>+</sup> plasmablasts) (both stable and progressive,  
535 n=51). Linear regression is shown with 95% confidence interval (gray area). Correlation  
536 statistics is two-tailed Spearman's rank correlation test.

537 **Supplemental Figure Legends**

538 **Supplemental Figure 1**

539 **The characteristics of each B cell subset in scRNA-seq dataset.**

540 **a**, Bar plot showing cell compositions of each cluster by samples. **b**, Box plot showing other  
541 canonical markers. The median is marked by a horizontal line with whiskers extending to the  
542 farthest point within a maximum of 1.5 x interquartile range. Each dot corresponds to each  
543 sample. **c**, Simpson's diversity of B cell clones within each plasmablast cluster. Each dot  
544 corresponds to a patient (combined early and late samples), and dots from the same patient  
545 are connected with dotted lines. **d**, The proportion of unmutated clones within each cell type  
546 cluster based on immunoglobulin isotypes. Each dot corresponds to a patient, and a Wilcoxon  
547 test p value is reported above plasmablast clusters. **e**, Comparison of cell counts (percentage  
548 of total B cells) among each group (one-way ANOVA with Dunnett's multiple comparisons test).  
549 Each dot corresponds to each sample, and One-way ANOVA with Dunn's multiple  
550 comparisons test was performed. **f**, Heatmap of gene expressions related to B cell functions<sup>31</sup>  
551 in each cluster. All the samples are evaluated.

552

553 **Supplemental Figure 2**

554 **The characteristics of each T cell subset.**

555 **a**, Gating strategy to identify each T cell subset in PBMCs. Six subsets were detected based  
556 on the expression levels of PD-1 and CXCR5, and activated T cells were defined as HLA-  
557 DR<sup>+</sup>CD38<sup>+</sup> T cells. **b**, The proportion of each T cell subset among healthcare workers (HC)  
558 (n=55), stable COVID-19 patients (Stable) (n=56), and progressive patients (Progressive)  
559 (n=36). One-way ANOVA with Dunn's multiple comparisons tests were evaluated. n.s. = no  
560 significance among each group. **c**, Correlation between each T cell subset (percentage of  
561 CD3<sup>+</sup>CD4<sup>+</sup>CD45RA<sup>-</sup> memory T cells) and plasmablasts (percentage of CD19<sup>+</sup> B cells) in  
562 COVID-19 patients (both stable and progressive, n=51). Linear regression is shown with 95%  
563 confidence interval (gray area). Correlation statistics is two-tailed Spearman's rank correlation  
564 test.

565

566 **Supplemental Figure 3**

567 **The characteristics of PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells.**

568 **a-b**, Correlation between the proportion of PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells (percentage of  
569 CD3+CD4<sup>+</sup>CD45RA<sup>-</sup> memory T cells) and each clinical background in COVID-19 patients  
570 (both stable and progressive, n=92) (**a**, age; **b**, BMI). Linear regression is shown with 95%  
571 confidence interval (gray area). Correlation statistics by two-tailed Spearman's rank  
572 correlation test (**a**, **b**). **c**, The proportion of PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells between male (n=45)  
573 and female (n=47) COVID-19 patients were evaluated by two-tailed unpaired Student's t-test.  
574 **d**, Representative flow data of CX3CR1 expression on PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells compared  
575 with PD-1<sup>high</sup>CXCR5<sup>+</sup> Tfh cells. **e**, Heatmap of T cell lineage genes among six subsets of  
576 memory CD4<sup>+</sup> T cells.

577

#### 578 **Supplemental Figure 4**

##### 579 **PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells from another COVID-19 dataset.**

580 Deposited flow cytometry data from another study<sup>6</sup> were analyzed for validation of the  
581 characteristics of PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells in the acute phase of COVID-19 patients. **a**,  
582 Representative flow data of PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells in healthy donors (HC), recovered  
583 donors from COVID-19 (RD), and hospitalized COVID-19 patients (COVID). **b**, The proportion  
584 of PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells among HC (n=56), RD (n=36), and COVID (n=109; all at baseline  
585 samples) groups. One-way ANOVA with Dunn's multiple comparisons tests were performed  
586 to evaluate differences. **c**, Correlation between PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells (percentage of  
587 CD3<sup>+</sup>CD4<sup>+</sup>CD45RA<sup>-</sup> non-naive T cells) and plasmablasts (percentage of CD19<sup>+</sup> B cells) in  
588 COVID-19 patients (n=109). Linear regression is shown with 95% confidence interval (gray  
589 area). Correlation statistics is two-tailed Spearman's rank correlation test.

590

#### 591 **Supplemental Figure 5**

##### 592 **The characteristics of HLA-DR+CD38+ activated PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells.**

593 **a**, Representative flow data of CXCR6 and LAG3 on each T cell subset. **b**, LAG3 (left) and  
594 CXCR6 (right) gMFI of each T cell subset were evaluated (n=4, COVID-19 patients). **c-d**,  
595 Correlation between the proportion of activated HLA-DR<sup>+</sup>CD38<sup>+</sup>PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells  
596 (percentage of PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells) and each clinical background in COVID-19 patients  
597 (both stable and progressive, n=92)(**c**, age; **d**, BMI). Linear regression is shown with 95%  
598 confidence interval (gray area). Correlation statistics is two-tailed Spearman's rank correlation  
599 test (**c**, **d**). **e**, The proportion of activated HLA-DR<sup>+</sup>CD38<sup>+</sup>PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells between

600 male (n=45) and female (n=47) COVID-19 patients were evaluated by two-tailed unpaired  
601 Student's t-test. **f-g**, Longitudinal frequencies of PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells (**f**) and activated  
602 PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells (**g**) after hospitalization. Only the samples which could follow blood  
603 collection (hospitalization, week1 of day1-7, week2 of day8-14) were analyzed (Stable n=23,  
604 Progressive n=16). At each time point, Two-tailed unpaired Student's t-test were performed  
605 (\*p<0.05).

606

### 607 **Supplemental Figure 6**

#### 608 **Schematic model of T-B interactions in a) healthy donors, b) stable COVID-19** 609 **patients, and c) progressive COVID-19 patients in acute phase.**

610 Under healthy conditions, we can detect few plasmablasts and PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells. In  
611 the acute phase, PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells increased in COVID-19 patients and are related  
612 to the promotion of plasmablasts. Among patients with COVID-19, stable groups can increase  
613 activated PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells quickly, which can produce IFN $\gamma$  more than PD-  
614 1<sup>high</sup>CXCR5<sup>+</sup> Tfh cells, and promote inflammatory-tissue homing plasmablasts at the proper  
615 timing. Progressive COVID-19 patients can also increase activated PD-1<sup>high</sup>CXCR5<sup>-</sup>Tph cells  
616 but delayed, which lead to insufficient promotion of plasmablasts at proper timing and worse  
617 clinical outcome.

618

619 **Acknowledgments**

620 We would like to thank all the hospital staff who helped care for the patients and obtain  
621 samples. We are also grateful to all the members of YALE IMPACT research team who  
622 obtained data. We also thank Yale Environmental Health and Safety (EHS) office,  
623 particularly Dr. Maren Schniederberend, for providing the safety guidance for working with  
624 COVID19 samples; Dr. Kevin O'Connor and C. Philip for feedback and discussions; Drs. L.  
625 Devine and C. Wang for assistance with FACS based cell sorting; Drs. G. Wang and C.  
626 Castaldi at Yale Center for Genome Analysis for support with 10x Genomics library  
627 preparation and sequencing. We also thank Mei Zhang for preparation of bulk RNA-seq  
628 libraries and sequencing. H.A. thanks Daiichi Sankyo Foundation of Life Science and  
629 Uehara Memorial Foundation for his scholarship. D.A.H, A.I., S.H.K., R.R.M., and A.C.S.  
630 thank the HIPC Consortium for valuable input.

631

632 **Funding statement**

633 This study was supported by grants to D.A.H. from the National Institutes of Health (NIH)  
634 (U19 AI089992, R25 NS079193, P01 AI073748, U24 AI11867, R01 AI22220, UM  
635 1HG009390, P01 AI039671, P50 CA121974, and R01 CA227473), the National Multiple  
636 Sclerosis Society (NMSS) (CA 1061- A-18 and RG-1802-30153), the Nancy Taylor  
637 Foundation for Chronic Diseases, and Erase MS (D.A.H); N.K. from NIH (R01HL127349,  
638 R01HL141852 and U01HL145567); K.B.H. and S.H.K. from NIH (R01AI104739); A.I. from  
639 NIH (R01AI157488 and R01NS111242) ; A.C.S. from NIH (K24AG042489). RNA sequencing  
640 service was conducted at Yale Center for Genome Analysis and Yale Stem Cell Center  
641 Genomics Core facility, the latter supported by the Connecticut Regenerative Medicine  
642 Research Fund and the Li Ka Shing Foundation.

643

644 **Competing interest statement**

645 D.A.H. has received research funding from Bristol-Myers Squibb, Novartis, Sanofi, and  
646 Genentech. He has been a consultant for Bayer Pharmaceuticals, Bristol Myers Squibb,  
647 Compass Therapeutics, EMD Serono, Genentech, Juno therapeutics, Novartis  
648 Pharmaceuticals, Proclara Biosciences, Sage Therapeutics, and Sanofi Genzyme. Further  
649 information regarding funding is available on:

650 <https://openpaymentsdata.cms.gov/physician/166753/general-payments>

651 N.K. reports personal fees from Boehringer Ingelheim, Third Rock, Pliant, Samumed,  
652 NuMedii, Indalo, Theravance, LifeMax, Three Lake Partners, RohBar in the last 36 months,  
653 and Equity in Pliant. N.K. is also a recipient of a grant from Veracyte and nonfinancial  
654 support from Miragen. In addition, N.K. has patents on New Therapies in Pulmonary Fibrosis  
655 and ARDS (unlicensed) and Peripheral Blood Gene Expression as biomarkers in IPF  
656 (licensed to biotech) all outside the submitted work. S.H.K. receives consulting fees from  
657 Northrop Grumman.

658

### 659 **Author Contributions**

660 Overall study design; H.A., D.A.H., T.S.S.

661 Biospecimen collection/processing; H.A., M.S., M.C., W.E.R., P.W., K.R., O.C., A.U., B.E.,  
662 R.R.M., A.I., A.C.S, T.S.S.

663 Data analysis; H.A., W.R., K.B.H., I.C., S.C., S.H.K., C.D.C., N.K.,

664 Original draft writing; H.A.

665 Supervising the study; S.H.K., C.D.C., N.K., A.C.S, D.A.H., T.S.S.

666 Reviewing and editing the manuscript; All authors participated in editing the manuscript.

667

668

669



670 **References**


- 671 1. Wu, Z. & McGoogan, J. M. Characteristics of and Important Lessons from the  
672 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of  
673 72314 Cases from the Chinese Center for Disease Control and Prevention. *JAMA - J.*  
674 *Am. Med. Assoc.* **323**, 1239–1242 (2020).
- 675 2. Zhu, N. *et al.* A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N.*  
676 *Engl. J. Med.* **382**, 727–733 (2020).
- 677 3. Takahashi, T. *et al.* Sex differences in immune responses that underlie COVID-19  
678 disease outcomes. *Nature* **588**, 315–320 (2020).
- 679 4. Giamarellos-Bourboulis, E. J. *et al.* Complex Immune Dysregulation in COVID-19  
680 Patients with Severe Respiratory Failure. *Cell Host Microbe* **27**, 992-1000.e3 (2020).
- 681 5. Unterman, A. *et al.* Single-Cell Omics Reveals Dyssynchrony of the Innate and  
682 Adaptive Immune System in Progressive COVID-19. *medRxiv* 2020.07.16.20153437  
683 (2020). doi:10.1101/2020.07.16.20153437
- 684 6. Mathew, D. *et al.* Deep immune profiling of COVID-19 patients reveals patient  
685 heterogeneity and distinct immunotypes with implications for therapeutic interventions.  
686 *Science* **369**, eabc8511 (2020).
- 687 7. Kratzer, B. *et al.* Immunological imprint of COVID-19 on human peripheral blood  
688 leukocyte populations. *Allergy* (2020). doi:10.1111/all.14647
- 689 8. Liao, M. *et al.* Single-cell landscape of bronchoalveolar immune cells in patients with  
690 COVID-19. *Nat. Med.* **26**, 842–844 (2020).
- 691 9. McElroy, A. K. *et al.* Human Ebola virus infection results in substantial immune  
692 activation. *Proc. Natl. Acad. Sci.* **112**, 4719–4724 (2015).
- 693 10. Wrammert, J. *et al.* Rapid and Massive Virus-Specific Plasmablast Responses during  
694 Acute Dengue Virus Infection in Humans. *J. Virol.* **86**, 2911–2918 (2012).
- 695 11. Alon, R. *et al.* Leukocyte trafficking to the lungs and beyond: lessons from influenza  
696 for COVID-19. *Nat. Rev. Immunol.* **21**, 49–64 (2021).
- 697 12. Kunkel, E. J. & Butcher, E. C. Plasma-cell homing. *Nat. Rev. Immunol.* **3**, 822–829  
698 (2003).
- 699 13. Nutt, S. L., Hodgkin, P. D., Tarlinton, D. M. & Corcoran, L. M. The generation of  
700 antibody-secreting plasma cells. *Nat. Rev. Immunol.* **15**, 160–171 (2015).
- 701 14. Ueno, H. T follicular helper cells in human autoimmunity. *Curr. Opin. Immunol.* **43**,  
702 24–31 (2016).
- 703 15. Crotty, S. Review T Follicular Helper Cell Biology : A Decade of Discovery and  
704 Diseases. *Immunity* **50**, 1132–1148 (2019).
- 705 16. Morita, R. *et al.* Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular

- 706 cells and contain specific subsets that differentially support antibody secretion.  
707 *Immunity* **34**, 108–121 (2011).
- 708 17. Juno, J. A. *et al.* Humoral and circulating follicular helper T cell responses in  
709 recovered patients with COVID-19. *Nat. Med.* **26**, 1428–1434 (2020).
- 710 18. Kaneko, N. *et al.* Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal  
711 Centers in COVID-19. *Cell* **183**, 143-157.e13 (2020).
- 712 19. Rao, D. A. *et al.* Pathologically expanded peripheral T helper cell subset drives B cells  
713 in rheumatoid arthritis. *Nature* **542**, 110–114 (2017).
- 714 20. Yoshitomi, H. & Ueno, H. Shared and distinct roles of T peripheral helper and T  
715 follicular helper cells in human diseases. *Cell. Mol. Immunol.* (2020).  
716 doi:10.1038/s41423-020-00529-z
- 717 21. Lucas, C. *et al.* Longitudinal analyses reveal immunological misfiring in severe  
718 COVID-19. *Nature* **584**, 463–469 (2020).
- 719 22. Zhang, J.-Y. *et al.* Single-cell landscape of immunological responses in patients with  
720 COVID-19. *Nat. Immunol.* **21**, 1107–1118 (2020).
- 721 23. Won, W.-J. & Kearney, J. F. CD9 Is a Unique Marker for Marginal Zone B Cells, B1  
722 Cells, and Plasma Cells in Mice. *J. Immunol.* **168**, 5605 LP – 5611 (2002).
- 723 24. Yoon, S.-O. *et al.* CD9 is a novel marker for plasma cell precursors in human germinal  
724 centers. *Biochem. Biophys. Res. Commun.* **431**, 41–46 (2013).
- 725 25. Kim, C. C., Baccarella, A. M., Bayat, A., Pepper, M. & Fontana, M. F. FCRL5+  
726 Memory B Cells Exhibit Robust Recall Responses. *Cell Rep.* **27**, 1446-1460.e4  
727 (2019).
- 728 26. Pérez-Mazliah, D., Ndungu, F. M., Aye, R. & Langhorne, J. B-cell memory in malaria:  
729 Myths and realities. *Immunol. Rev.* **293**, 57–69 (2020).
- 730 27. Jenks, S. A. *et al.* Distinct Effector B Cells Induced by Unregulated Toll-like Receptor  
731 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus. *Immunity*  
732 **49**, 725-739.e6 (2018).
- 733 28. Riedel, R. *et al.* Discrete populations of isotype-switched memory B lymphocytes are  
734 maintained in murine spleen and bone marrow. *Nat. Commun.* **11**, 2570 (2020).
- 735 29. Sanz, I. *et al.* Challenges and Opportunities for Consistent Classification of Human B  
736 Cell and Plasma Cell Populations. *Front. Immunol.* **10**, 2458 (2019).
- 737 30. Jenks, S. A., Cashman, K. S., Woodruff, M. C., Lee, F. E.-H. & Sanz, I. Extrafollicular  
738 responses in humans and SLE. *Immunol. Rev.* **288**, 136–148 (2019).
- 739 31. Glass, D. R. *et al.* An Integrated Multi-omic Single-Cell Atlas of Human B Cell Identity.  
740 *Immunity* **53**, 217-232.e5 (2020).
- 741 32. Pattanapanyasat, K. *et al.* B cell subset alteration and the expression of tissue homing

- 742 molecules in dengue infected patients. *J. Biomed. Sci.* **25**, 64 (2018).
- 743 33. Muehlinghaus, G. *et al.* Regulation of CXCR3 and CXCR4 expression during terminal  
744 differentiation of memory B cells into plasma cells. *Blood* **105**, 3965–3971 (2005).
- 745 34. Bocharnikov, A. V *et al.* PD-1hiCXCR5<sup>+</sup> T peripheral helper cells promote B cell  
746 responses in lupus via MAF and IL-21. *JCI Insight* **4**, e130062 (2019).
- 747 35. Conigliaro, P. *et al.* The type I IFN system in rheumatoid arthritis. *Autoimmunity* **43**,  
748 220–225 (2010).
- 749 36. Muskardin, T. L. W. & Niewold, T. B. Type I interferon in rheumatic diseases. *Nat.*  
750 *Rev. Rheumatol.* **14**, 214–228 (2018).
- 751 37. Schmitt, N. *et al.* The cytokine TGF- $\beta$  2 co-opts signaling via STAT3-STAT4 to  
752 promote the differentiation of human TFH cells. *Nat. Immunol.* **15**, 856–865 (2014).
- 753 38. Sumida, T. S. *et al.* Type I Interferon Transcriptional Network Regulates Expression of  
754 Coinhibitory Receptors in Human T cells. *bioRxiv: the preprint server for biology*  
755 (2020). doi:10.1101/2020.10.30.362947
- 756 39. Woodruff, M. C. *et al.* Extrafollicular B cell responses correlate with neutralizing  
757 antibodies and morbidity in COVID-19. *Nat. Immunol.* **21**, 1506–1516 (2020).
- 758 40. Ramaswamy, A. *et al.* Post-infectious inflammatory disease in MIS-C features  
759 elevated cytotoxicity signatures and autoreactivity that correlates with severity.  
760 *medRxiv: the preprint server for health sciences* (2020).  
761 doi:10.1101/2020.12.01.20241364
- 762 41. Lam, J. H. & Baumgarth, N. The Multifaceted B Cell Response to Influenza Virus. *J.*  
763 *Immunol.* **202**, 351–359 (2019).
- 764 42. Elsner, R. A. & Shlomchik, M. J. Germinal Center and Extrafollicular B Cell  
765 Responses in Vaccination, Immunity, and Autoimmunity. *Immunity* **53**, 1136–1150  
766 (2020).
- 767 43. Cunningham, A. F. *et al.* Salmonella induces a switched antibody response without  
768 germinal centers that impedes the extracellular spread of infection. *J. Immunol.* **178**,  
769 6200–6207 (2007).
- 770 44. Lucas, C. *et al.* Kinetics of antibody responses dictate COVID-19 outcome. *medRxiv*  
771 2020.12.18.20248331 (2020). doi:10.1101/2020.12.18.20248331
- 772 45. Chen, Y. *et al.* A comprehensive, longitudinal analysis of humoral responses specific  
773 to four recombinant antigens of SARS-CoV-2 in severe and non-severe COVID-19  
774 patients. *PLOS Pathog.* **16**, e1008796 (2020).
- 775 46. Kofler, D. M., Severson, C. A., Mousissian, N., De Jager, P. L. & Hafler, D. A. The  
776 CD6 multiple sclerosis susceptibility allele is associated with alterations in CD4<sup>+</sup> T  
777 cell proliferation. *J. Immunol.* **187**, 3286–3291 (2011).


- 778 47. Karakas Celik, S., Cakmak Genc, G. & Dursun, A. A bioinformatic approach to  
779 investigating cytokine genes and their receptor variants in relation to COVID-19  
780 progression. *Int. J. Immunogenet.* (2020). doi:10.1111/iji.12522
- 781 48. Remy, M. M. *et al.* Effective chemical virus inactivation of patient serum compatible  
782 with accurate serodiagnosis of infections. *Clin. Microbiol. Infect. Off. Publ. Eur.*  
783 *Soc. Clin. Microbiol. Infect. Dis.* **25**, 907.e7-907.e12 (2019).
- 784 49. Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell  
785 transcriptomic data across different conditions, technologies, and species. *Nat.*  
786 *Biotechnol.* **36**, 411–420 (2018).
- 787 50. Stuart, T. *et al.* Comprehensive Integration of Single-Cell Data. *Cell* **177**, 1888-  
788 1902.e21 (2019).
- 789 51. Giudicelli, V., Chaume, D. & Lefranc, M.-P. IMGT/GENE-DB: a comprehensive  
790 database for human and mouse immunoglobulin and T cell receptor genes. *Nucleic*  
791 *Acids Res.* **33**, D256-61 (2005).
- 792 52. Ye, J., Ma, N., Madden, T. L. & Ostell, J. M. IgBLAST: an immunoglobulin variable  
793 domain sequence analysis tool. *Nucleic Acids Res.* **41**, W34-40 (2013).
- 794 53. Gupta, N. T. *et al.* Change-O: a toolkit for analyzing large-scale B cell immunoglobulin  
795 repertoire sequencing data. *Bioinformatics* **31**, 3356–3358 (2015).
- 796 54. Yaari, G. *et al.* Models of somatic hypermutation targeting and substitution based on  
797 synonymous mutations from high-throughput immunoglobulin sequencing data.  
798 *Front. Immunol.* **4**, 358 (2013).
- 799 55. Nielsen, S. C. A. *et al.* Human B Cell Clonal Expansion and Convergent Antibody  
800 Responses to SARS-CoV-2. *Cell Host Microbe* **28**, 516-525.e5 (2020).
- 801 56. Cantu, V. A., Sadural, J. & Edwards, R. PRINSEQ++, a multi-threaded tool for fast  
802 and efficient quality control and preprocessing of sequencing datasets. *PeerJ Prepr.*  
803 43–45 (2019). doi:10.7287/peerj.preprints.27553
- 804 57. Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15–21  
805 (2013).
- 806 58. Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data  
807 with or without a reference genome. *BMC Bioinformatics* **12**, 323 (2011).
- 808 59. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and  
809 dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).

810




**Figure 1 The divergent immunological features of B cells in stable and progressive COVID-19 patients**

Plasmablasts of patients with stable COVID-19 express inflammatory tissue-homing receptors. **a**, Representative flow data of CD19<sup>+</sup>CD27<sup>+</sup>CD38<sup>+</sup> plasmablasts (left). The proportion of plasmablasts between healthcare workers (HCs) (n=15) and both stable and progressive COVID-19 patients (COVID) (n=51) were evaluated by two-tailed unpaired Student's t-test (right). **b**, UMAP representation of sub-clustered B cells from HCs (n = 13) and COVID-19 samples (n = 18 from 10 patients). Eight subclusters were identified. **c**, Canonical cell markers for cluster delineation. Data are colored according to expression levels. **d**, Fractional abundance of IGHA (dark green), IGHD (orange), IGHG (pink), and IGHM (light green) cells in each cluster. PBs denote plasmablasts. **e**, Frequency of somatic hypermutation (SHM) in each cluster. Each dot denotes a patient (combined early and late samples, n=10). A Wilcoxon test was evaluated, and p value is reported above plasmablast clusters. PBs denote plasmablasts. **f**, Heatmap of tissue-homing receptors<sup>32</sup> among HC, stable COVID-19 (stable), and progressive COVID-19 (progressive) in clusters of both plasmablasts and Ki67<sup>+</sup> plasmablasts. Average expression per subject for each gene is shown. **g**, Representative flow data of CXCR3 expression on CD19<sup>+</sup>CD27<sup>+</sup>CD38<sup>+</sup> plasmablasts in COVID-19 patients (left). The proportions of CXCR3<sup>+</sup> plasmablasts between stable (n= 31) and progressive (n=20) COVID-19 patients were evaluated by two-tailed unpaired Student's t-test (right).




**Figure 2 The characteristics of PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells**

PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells have characteristic gene expressions and are increased in COVID-19 patients. **a**, Representative flow data of PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells in each group (left), the proportion of these T cells among healthcare workers (HC) (n=55), stable COVID-19 patients (Stable) (n=56), and progressive patients (Progressive) (n=36). One-way ANOVA with Dunn's multiple comparisons tests were performed to evaluate differences (right). **b**, Correlation between PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells (percentage of CD3<sup>+</sup>CD4<sup>+</sup>CD45RA<sup>-</sup> memory T cells) and plasmablasts (percentage of CD19<sup>+</sup> B cells) in COVID-19 patients (both stable and progressive, n=51). Linear regression is shown with 95% confidence interval (gray area). Correlation statistics is two-tailed Spearman's rank correlation test. **c**, Principal component analysis (PCA) of RNA-seq transcriptomes (n=3, COVID-19 patients). Based on the expression levels of memory CD4<sup>+</sup> T cells, six subsets (i)-(vi) were evaluated **d**, Heatmap of Tfh-related genes19 among six subsets of memory CD4<sup>+</sup> T cells. **e**, Clustered heatmap of 100 genes that were differentially expressed (left column) in PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells compared with cTfh cells (PD-1<sup>high</sup>CXCR5<sup>+</sup> Tph cells) ( $|\text{Log}_2\text{FC}| > 1$ , FDR < 0.05). The right column shows the log2 fold change for PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells compared to cTfh cells. **f**, Representative flow data of CCR5 and CCR2 expression on PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells compared with PD-1<sup>high</sup>CXCR5<sup>+</sup> Tph cells.



**Figure 3 The functions of PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells**


PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells promote B cell differentiation and produce IFN $\gamma$  much higher than cTfh cells, which affects the expression levels of tissue-homing receptors on plasmablasts. **a-b**, Each T cell subset and autologous CD20<sup>+</sup>CD27<sup>+</sup> B cells were sorted and co-cultured with SEB and LPS for 7 days (n=5, COVID-19 patients). Representative flow data of CD27<sup>high</sup>CD138<sup>+</sup> plasma cells after co-culture (**a**). IgG concentrations in supernatants of co-cultures were evaluated by One-way ANOVA with Dunn's multiple comparisons tests (**b**). **c**, Sorted T cells (n=4, COVID-19 patients) were stimulated with anti-CD3/28 (each 1  $\mu$ g/ml) for 48 hrs, then cytokine production levels were measured (IFN $\gamma$ , IL-17A, IL-10). **d-f**, Sorted CD20<sup>+</sup>CD27<sup>+</sup> memory B cells (n=5, healthy donors) were cultured with CD40L (0.05 ng/ml), IL-21 (20ng/ml), and IL-10 (10 ng/ml) or different concentration of IFN $\gamma$  (0, 3, 10, 30 ng/ml) for 7 days (n=5, healthy controls). Representative histogram of flow data for CXCR3 expression on plasma cells (**d**, left), CXCR3 gMFI was evaluated by One-way ANOVA with Tukey's multiple comparisons tests (**d**, right). After 7 days in culture, CD19<sup>+</sup>CD27<sup>+</sup>CD138<sup>+</sup> plasma cells were sorted and gene expression measured relative to B2M by qPCR (**e**, **f**). The expression levels were evaluated by One-way ANOVA with Tukey's multiple comparisons tests (**c-f**).



**Figure 4 Activated PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells are significantly increased in stable COVID-19 patients and positively correlated with CXCR3<sup>+</sup> plasmablasts**


**a**, Venn diagrams showing the overlapped genes among those significantly upregulated (Log<sub>2</sub>FC>1, FDR<0.05) (left) and downregulated (Log<sub>2</sub>FC<-1, FDR<0.05) (right) in PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells compared with five subsets as indicated. **b**, Heatmap of PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells-related genes (selected in a) among each T cell subset from RNA-seq data. **c**, Heatmap of PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells-related genes (selected in a) among each T cell cluster of our scRNA-seq dataset reported<sup>5</sup>. **d**, Representative flow data for each T cell subset among HLA-DR<sup>+</sup>CD38<sup>+</sup>CD45RA<sup>-</sup>CD4<sup>+</sup> T cells (left), and their proportions were evaluated by One-way ANOVA with Dunn's multiple comparisons tests (right). COVID-19 samples which have more than 5% of HLA-DR<sup>+</sup>CD38<sup>+</sup> T cells among memory CD4<sup>+</sup> T cells were evaluated (n=11). **e**, Representative flow data of HLA-DR<sup>+</sup>CD38<sup>+</sup> activated cells in PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells between stable and progressive COVID-19 patients (up). The proportions of activated PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells were evaluated (stable; n= 56, progressive; n= 36) by two-tailed Student's t-test (down). **f**, Correlation between activated PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells (percentage of CD3<sup>+</sup>CD4<sup>+</sup>CD45RA<sup>-</sup> memory T cells) and CXCR3<sup>+</sup> plasmablasts (percentage of CD19<sup>+</sup>CD27<sup>+</sup>CD38<sup>+</sup> plasmablasts) (both stable and progressive, n=51). Linear regression is shown with 95% confidence interval (gray area). Correlation statistics is two-tailed Spearman's rank correlation test.






### Supplemental Figure 1 The characteristics of each B cell subset in scRNA-seq dataset

**a**, Bar plot showing cell compositions of each cluster by samples. **b**, Box plot showing other canonical markers. The median is marked by a horizontal line with whiskers extending to the farthest point within a maximum of 1.5 x interquartile range. Each dot corresponds to each sample. **c**, Simpson's diversity of B cell clones within each plasmablast cluster. Each dot corresponds to a patient (combined early and late samples), and dots from the same patient are connected with dotted lines. **d**, The proportion of unmutated clones within each cell type cluster based on immunoglobulin isotypes. Each dot corresponds to a patient, and a Wilcoxon test p value is reported above plasmablast clusters. **e**, Comparison of cell counts (percentage of total B cells) among each group (one-way ANOVA with Dunnett's multiple comparisons test). Each dot corresponds to each sample, and One-way ANOVA with Dunn's multiple comparisons test was performed. **f**, Heatmap of gene expressions related to B cell functions<sup>31</sup> in each cluster. All the samples are evaluated.




**Supplemental Figure 2 The characteristics of each T cell subset**

**a**, Gating strategy to identify each T cell subset in PBMCs. Six subsets were detected based on the expression levels of PD-1 and CXCR5, and activated T cells were defined as HLA-DR<sup>+</sup>CD38<sup>+</sup> T cells. **b**, The proportion of each T cell subset among healthcare workers (HC) (n=55), stable COVID-19 patients (Stable) (n=56), and progressive patients (Progressive) (n=36). One-way ANOVA with Dunn's multiple comparisons tests were evaluated. n.s. = no significance among each group. **c**, Correlation between each T cell subset (percentage of CD3<sup>+</sup>CD4<sup>+</sup>CD45RA<sup>-</sup> memory T cells) and plasmablasts (percentage of CD19<sup>+</sup> B cells) in COVID-19 patients (both stable and progressive, n=51). Linear regression is shown with 95% confidence interval (gray area). Correlation statistics is two-tailed Spearman's rank correlation test.




**Supplemental Figure 3 The characteristics of PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells.**

**a-b**, Correlation between the proportion of PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells (percentage of CD3<sup>+</sup>CD4<sup>+</sup>CD45RA<sup>-</sup> memory T cells) and each clinical background in COVID-19 patients (both stable and progressive, n=92) (**a**, age; **b**, BMI). Linear regression is shown with 95% confidence interval (gray area). Correlation statistics by two-tailed Spearman's rank correlation test (**a**, **b**). **c**, The proportion of PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells between male (n=45) and female (n=47) COVID-19 patients were evaluated by two-tailed unpaired Student's t-test. **d**, Representative flow data of CX3CR1 expression on PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells compared with PD-1<sup>high</sup>CXCR5<sup>+</sup> Tfh cells. **e**, Heatmap of T cell lineage genes among six subsets of memory CD4<sup>+</sup> T cells.



**Supplemental Figure 4 PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells from another COVID-19 dataset**

Deposited flow cytometry data from another study<sup>6</sup> were analyzed for validation of the characteristics of PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells in the acute phase of COVID-19 patients. **a**, Representative flow data of PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells in healthy donors (HC), recovered donors from COVID-19 (RD), and hospitalized COVID-19 patients (COVID). **b**, The proportion of PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells among HC (n=56), RD (n=36), and COVID (n=109; all at baseline samples) groups. One-way ANOVA with Dunn's multiple comparisons tests were performed to evaluate differences. **c**, Correlation between PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells (percentage of CD3<sup>+</sup>CD4<sup>+</sup>CD45RA<sup>-</sup> non-naive T cells) and plasmablasts (percentage of CD19<sup>+</sup> B cells) in COVID-19 patients (n=109). Linear regression is shown with 95% confidence interval (gray area). Correlation statistics is two-tailed Spearman's rank correlation test.




**Supplemental Figure 5 The characteristics of HLA-DR<sup>+</sup>CD38<sup>+</sup> activated PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells**

**a**, Representative flow data of CXCR6 and LAG3 on each T cell subset. **b**, LAG3 (left) and CXCR6 (right) gMFI of each T cell subset were evaluated (n=4, COVID-19 patients). **c-d**, Correlation between the proportion of activated HLA-DR<sup>+</sup>CD38<sup>+</sup>PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells (percentage of PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells) and each clinical background in COVID-19 patients (both stable and progressive, n=92) (**c**, age; **d**, BMI). Linear regression is shown with 95% confidence interval (gray area). Correlation statistics is two-tailed Spearman's rank correlation test (**c**, **d**). **e**, The proportion of activated HLA-DR<sup>+</sup>CD38<sup>+</sup>PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells between male (n=45) and female (n=47) COVID-19 patients were evaluated by two-tailed unpaired Student's t-test. **f-g**, Longitudinal frequencies of PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells (**f**) and activated PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells (**g**) after hospitalization. Only the samples which could follow blood collection (hospitalization, week1 of day1-7, week2 of day8-14) were analyzed (Stable n=23, Progressive n=16). At each time point, Two-tailed unpaired Student's t-test were performed (\*p<0.05).

## COVID-19

## HC



**Supplemental Figure 6 Schematic model of T-B interactions in a) healthy donors, b) stable COVID-19 patients, and c) progressive COVID-19 patients in acute phase**

Under healthy conditions, we can detect few plasmablasts and PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells. In the acute phase, PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells increased in COVID-19 patients and are related to the promotion of plasmablasts. Among patients with COVID-19, stable groups can increase activated PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells quickly, which can produce IFN<sub>γ</sub> more than PD-1<sup>high</sup>CXCR5<sup>+</sup> Tfh cells, and promote inflammatory-tissue homing plasmablasts at the proper timing. Progressive COVID-19 patients can also increase activated PD-1<sup>high</sup>CXCR5<sup>-</sup> Tph cells but delayed, which lead to insufficient promotion of plasmablasts at proper timing and worse clinical outcome.